Replies to post #61755 on CV Sciences Inc (CVSI)

[Gladys Thong]

I think consumers are more eager to purchase "CBD" than "Hemp extract"

Apparently not.

Even now, early in consumer education and company marketing, Charlotte's Web products outsold CV Sciences' 2 to 1 in Q3 -- $25.1M vs $12.6M.

That difference will grow as Charlotte's Web's brand familiarity and differentiation grows and CV Sciences' "Plus CBD" continues to be overwhelmed by other generic-looking and sounding "<whatever>CBD" brands. Just look at the cacophony that already exists and the number is growing.

Additionally, the lack of "Plus CBD" brand differentiation is further complicated by the fact that "CBD", itself, is an FDA-identified drug which makes marketing ingestibles of brands that incorporate "CBD" in their names "iffy", at best, in many states -- approximately 1/3 of the US population.

So while I, like many CWBHF/CWEB investors, would have STRONGLY preferred that Charlotte's Web proceed without the need for an additional share offering, I see a much clearer path to success for it than for a company like CV Sciences which will likely face a need for REBRANDING, for the reasons identified above. Rebranding, particularly at this stage in establishing a market, would be not only expensive in CAPITAL but, especially, in TIME. A secondary offering would be the least of CV Sciences' shareholders' worries.